View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 3, 2022

Immatics and BMS expand cell therapy development partnership

Immatics will get development, regulatory and commercial milestone payments of up to $700m for each BMS programme.

Immatics has expanded a strategic Immatics -and-Bristol-Myers-Squibb-Expand-Strategic-Alliance-to-Develop-Gamma-Delta-Allogeneic-Cell-Therapy-Programs/default.aspx” target=”_blank” rel=”noreferrer noopener”>partnership with Bristol Myers Squibb (BMS) to develop multiple allogeneic off-the-shelf T cell receptor-based therapy (TCR-T) and/or chimeric antigen receptor T (CAR-T) programmes.

Under the alliance, the companies will develop two programmes owned by BMS and both of them will hold an option for developing up to four additional programmes each.

The programmes will leverage ACTallo, a gamma delta T cell-derived, allogeneic Adoptive Cell Therapy (ACT) platform of Immatics and various next-generation technologies of BMS.

As per the deal, Immatics is eligible to get $60m in upfront payment as well as development, regulatory and commercial milestone payments of up to $700m for each BMS programme.

In addition, Immatics will receive tiered royalty payments on net sales of the product.

Immatics will oversee the preclinical development of the first two BMS-owned programmes and get further payment for certain works that the former could carry out at the request of BMS.

BMS will handle the subsequent clinical development and marketing of all the programmes owned by the company.

Furthermore, the company agreed to expand a partnership entered in 2019 for autologous TCR-T, to include another Immatics -discovered TCR target. 

Under this alliance, Immatics is entitled to get $20m in upfront payment as well as milestone and royalty payments.

Bristol Myers Squibb Research & Early Development executive vice-president Rupert Vessey said: “The announcement represents an important part of our continued investment in next-generation cell therapies that have the potential to provide transformative outcomes to patients with cancer.

“We are excited to expand our collaboration with Immatics that allows us to combine their novel off-the-shelf platforms with our industry-leading research and manufacturing expertise in cell therapy to develop new allogeneic cell therapy treatments to potentially help patients with solid tumour malignancies.”

In May this year, BMS and BridgeBio Pharma signed an exclusive licence agreement to develop and market BBP-398 in oncology.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology